Arbutus Biopharma Corp
Fechado
5 0.2
Visão Geral
Variação de preço das ações
24h
Mín
4.99
Máximo
5.04
Rendimento | -175M -5.1M |
|---|---|
Vendas | -178M 1M |
P/E Médio do Setor | 6.494 56.432 |
EPS | -0.03 |
Margem de lucro | -507.199 |
Funcionários | 19 |
EBITDA | -175M -5.1M |
Próximos Ganhos | 12 de nov. de 2026 |
|---|
Capitalização de Mercado | 110M 1B |
|---|---|
Abertura anterior | 4.8 |
Fecho anterior | 5 |
Arbutus Biopharma Corp Gráfico
O desempenho passado não é um indicador confiável de resultados futuros.
Notícias Relacionadas
Comparação entre Pares
Variação de preço
Arbutus Biopharma Corp Previsão
Informação Financeira
Custos administrativos e de venda
Custos Operacionais
Lucro antes de imposto
Vendas
Custo das vendas
Lucro bruto sobre vendas
Despesa com juros da dívida
EBITDA
Resultado Operacional
$
Sobre Arbutus Biopharma Corp
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.